Immunai is a biotech company focused on mapping the entire immune system using single-cell genomics and machine learning. The company leverages advanced single-cell technologies to profile cells from blood samples and employs proprietary machine-learning algorithms to create detailed immune profiles. Immunai's mission is to revolutionize immune system understanding and biomarker discovery, targeting applications in immunotherapy and personalized medicine.
Immunai has made significant strides in the biotech industry, achieving high-resolution immune profiling that aids in the discovery of novel biomarkers and therapeutic targets. The company's innovative approach has garnered attention and investment from notable figures in the biotech and venture capital sectors. Immunai's work is paving the way for advancements in immunotherapy and personalized healthcare solutions.
